It's been a momentous few years for both Dengue and DENV antiviral development - particularly for the JNJ and NITD NS4B inhibitors. New preprint from my thesis lab sheds some light on the differences between the two companies' compounds (they don't work the same way):
www.biorxiv.org/content/10.1...
Mechanistic Insights into Dengue Virus Inhibition by a Clinical Trial Compound NITD-688
Dengue, caused by the dengue virus (DENV), presents a significant public health challenge with limited effective treatments. NITD-688 is a potent pan-serotype DENV inhibitor currently in Phase II clin...
